Giulia Lucca, Paolo Quaroni, Silvia Paparesta, Luca Ceroni, Camilla Callegari, Marco Innamorati, Maurizio Pompili, Nicola Poloni
{"title":"Assessing mental pain as a predictive factor of suicide risk in a clinical sample of patients with psychiatric disorders.","authors":"Giulia Lucca, Paolo Quaroni, Silvia Paparesta, Luca Ceroni, Camilla Callegari, Marco Innamorati, Maurizio Pompili, Nicola Poloni","doi":"10.1708/4617.46260","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Mental pain (psychache) is a key risk factor for suicide, surpassing traditional constructs like depression and anxiety. While its correlation with suicidal ideation is well-established, few studies have evaluated its predictive value for actual suicide attempts in clinical populations. This study aimed to evaluate whether mental pain predicts short-term suicide attempts in a clinical sample, and to assess its potential role as a screening tool in suicide prevention.</p><p><strong>Methods: </strong>A longitudinal study on 179 psychiatric outpatients recruited at the University Hospital of Varese between 2020 and 2022. At baseline, participants completed the Psychache Scale (PAS), Beck Hopelessness Scale (BHS), Beck Depression Inventory-II (BDI-II), and Columbia Suicide Severity Scale (C-SSRS), among others. Sociodemographic, clinical, and laboratory data were also collected. Suicide attempts were tracked over a 12-month follow-up. Binary logistic regression was used to identify predictors of suicide attempts.</p><p><strong>Results: </strong>Twenty-six patients attempted suicide during follow-up, with 24 cases occurring within the first 6 months. Higher scores on the PAS, BHS, BDI-II, and Columbia Severity Rating Scale (C-SSRS) were significantly associated with increased suicide risk. In logistic regression, the PAS emerged as an independent predictor: each point increase corresponded to a 3.8% rise in suicide attempt probability (p=0.015). The BDI-II showed the strongest model fit (R2=0.169). Unemployment and history of substance abuse were also significantly associated with increased risk. No significant associations were found with routine laboratory parameters.</p><p><strong>Conclusions: </strong>The PAS, alongside the BDI-II, BHS, and C-SSRS scales may serve as an effective tool for early suicide risk detection, especially in psychiatric and primary care settings. Mental pain appears to be a relevant short-term risk indicator, highlighting the need for targeted screening and prevention strategies. Further research should explore its application in general healthcare to enhance suicide prevention efforts.</p>","PeriodicalId":21506,"journal":{"name":"Rivista di psichiatria","volume":"60 6","pages":"270-278"},"PeriodicalIF":1.3000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rivista di psichiatria","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1708/4617.46260","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Mental pain (psychache) is a key risk factor for suicide, surpassing traditional constructs like depression and anxiety. While its correlation with suicidal ideation is well-established, few studies have evaluated its predictive value for actual suicide attempts in clinical populations. This study aimed to evaluate whether mental pain predicts short-term suicide attempts in a clinical sample, and to assess its potential role as a screening tool in suicide prevention.
Methods: A longitudinal study on 179 psychiatric outpatients recruited at the University Hospital of Varese between 2020 and 2022. At baseline, participants completed the Psychache Scale (PAS), Beck Hopelessness Scale (BHS), Beck Depression Inventory-II (BDI-II), and Columbia Suicide Severity Scale (C-SSRS), among others. Sociodemographic, clinical, and laboratory data were also collected. Suicide attempts were tracked over a 12-month follow-up. Binary logistic regression was used to identify predictors of suicide attempts.
Results: Twenty-six patients attempted suicide during follow-up, with 24 cases occurring within the first 6 months. Higher scores on the PAS, BHS, BDI-II, and Columbia Severity Rating Scale (C-SSRS) were significantly associated with increased suicide risk. In logistic regression, the PAS emerged as an independent predictor: each point increase corresponded to a 3.8% rise in suicide attempt probability (p=0.015). The BDI-II showed the strongest model fit (R2=0.169). Unemployment and history of substance abuse were also significantly associated with increased risk. No significant associations were found with routine laboratory parameters.
Conclusions: The PAS, alongside the BDI-II, BHS, and C-SSRS scales may serve as an effective tool for early suicide risk detection, especially in psychiatric and primary care settings. Mental pain appears to be a relevant short-term risk indicator, highlighting the need for targeted screening and prevention strategies. Further research should explore its application in general healthcare to enhance suicide prevention efforts.
背景:精神疼痛是自杀的关键风险因素,超过了抑郁和焦虑等传统因素。虽然其与自杀意念的相关性已得到证实,但很少有研究评估其对临床人群中实际自杀企图的预测价值。本研究旨在评估精神疼痛是否能在临床样本中预测短期自杀企图,并评估其作为自杀预防筛查工具的潜在作用。方法:对2020年至2022年在瓦雷塞大学医院招募的179名精神科门诊患者进行纵向研究。在基线时,参与者完成了精神疼痛量表(PAS)、贝克绝望量表(BHS)、贝克抑郁量表- ii (BDI-II)和哥伦比亚自杀严重程度量表(C-SSRS)等。还收集了社会人口学、临床和实验室数据。他们对自杀企图进行了为期12个月的跟踪调查。使用二元逻辑回归来确定自杀企图的预测因素。结果:随访期间有26例患者自杀未遂,其中24例发生在前6个月内。PAS、BHS、BDI-II和哥伦比亚严重程度评定量表(C-SSRS)得分越高,自杀风险越高。在逻辑回归中,PAS作为一个独立的预测因子出现:每增加一个点对应于3.8%的自杀企图概率上升(p=0.015)。BDI-II模型拟合最强(R2=0.169)。失业和药物滥用史也与风险增加显著相关。与常规实验室参数无显著相关性。结论:PAS与BDI-II、BHS和C-SSRS量表可以作为早期自杀风险检测的有效工具,特别是在精神科和初级保健机构。精神疼痛似乎是一个相关的短期风险指标,强调需要有针对性的筛查和预防策略。进一步的研究应探讨其在一般医疗保健中的应用,以加强自杀预防工作。
期刊介绍:
Gli interessi della rivista riguardano l’approfondimento delle interazioni tra mente e malattia, la validazione e la discussione dei nuovi strumenti e parametri di classificazione diagnostica, la verifica delle prospettive terapeutiche farmacologiche e non.